SCHEDULE: Highbridge Capital Discloses 7.2% Stake in BioLineRx
Beneficial Ownership Disclosure
Highbridge Capital Management, LLC has disclosed a 7.2% beneficial ownership stake in BioLineRx Ltd., primarily through warrants convertible into Ordinary Shares.
Summary
- Highbridge Capital Management, LLC, an investment adviser, reported beneficial ownership of 172,950,600 Ordinary Shares of BioLineRx Ltd.
- This stake represents 7.2% of BioLineRx Ltd.'s outstanding Ordinary Shares, calculated based on 2,232,601,990 Ordinary Shares outstanding as of May 15, 2025.
- The reported shares are issuable upon the exercise of warrants held by Highbridge Funds, specifically 288,251 American Depositary Shares (ADSs), with each ADS representing 600 Ordinary Shares.
- Highbridge Tactical Credit Master Fund, L.P., a Highbridge Fund, holds the right to receive dividends or proceeds from the sale of more than 5% of these Ordinary Shares.
- The acquisition of these securities was in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: This is a neutral regulatory filing disclosing a passive ownership stake. It does not contain information that would inherently indicate positive or negative sentiment regarding the company's operational performance or financial health.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive ownership stake by an investment adviser in a biotechnology company. It does not provide specific industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional investor's stake may be viewed as a positive signal of confidence, although the filing explicitly states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Key Dates
| Date | Description |
|---|---|
| 2025-05-15 | Date of outstanding Ordinary Shares calculation (2,232,601,990 shares). |
| 2025-05-23 | Date of Form 6-K filing reporting outstanding shares. |
| 2025-06-30 | Date of event requiring the filing of this statement. |
| 2025-08-14 | Date of Schedule 13G filing. |
Keywords
BioLineRx Ltd., BLRX, Highbridge Capital Management, Schedule 13G, Beneficial Ownership, Warrants, ADSs, Ordinary Shares, Investment Adviser, Nasdaq Capital Market
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.